Ashion® leverages pioneering clinical genomic sequencing and analysis technology developed through the research led by Drs. David Craig and John Carpten at The Translational Genomics Research Institute® (TGen®). Deploying this technology in a broader commercial context to expand the availability of these tools to help patients with cancer and other genetic diseases is Ashion’s number one priority. This technology was used in the world’s first clinical studies for personalized cancer treatment selection, and Ashion hopes to continue to partner with research collaborators for impactful clinical studies.
Ashion Analytics™ is proud to partner with Translational Genomics Research Institute® (TGen®) as its clinical sequencing provider for several important clinical studies, such as a precision medicine approach for metastatic melanoma patients, and a multicenter study to evaluate the feasibility of molecularly guided therapy in patients with relapsed or refractory childhood cancers
Ashion Analytics™ has the tools and experience to make your research project successful
Genomic sequencing, new protocols, the latest technologies, and computer algorithms have been deployed in these studies to assist with cancer diagnostics and personalized cancer therapy selection. Precise reporting of this information to referring physicians and their patients makes genomic information usable. These significant advancements, including the development of the GEM Cancer Panel™ (Ashion Analytics™ flagship clinical assay), combined with TGen technology and the extensive experience of the Ashion Analytics team, provide unparalleled diagnostic and therapeutic selection for patients.